The financial recovery process for Dublin-based medical device firm Narooma Limited remains mired in legal friction, as the company continues to chase a multimillion-euro settlement stemming from a collapsed Covid-19 procurement contract. Despite an International Chamber of Commerce (ICC) arbitration ruling that favored the firm, newly filed corporate accounts reveal that the Health Service Executive (HSE) has not yet satisfied the full obligation linked to a failed 2020 ventilator deal.
The Bottom Line:
- Narooma Limited is seeking a principal award of approximately €2.7 million, plus 2 percent annual interest accruing since March 19, 2021.
- The total liability facing the HSE, including legal and procedural costs, is estimated by the Irish Examiner to reach nearly €6 million.
- Narooma Limited reported a profit of €1.8 million in its latest fiscal year, which the Irish Times indicates was boosted by partial payments received from the HSE.
Narooma Pursues HSE for Ventilator Dispute Damages
The dispute traces back to April 2020, when Narooma Limited, owned by businessman John Ward, initiated legal proceedings against the HSE following the collapse of an agreement to supply 350 ventilators valued at €7.5 million. The ICC ruling issued last year finally provided a concrete valuation of the breach, mandating that the HSE pay the principal sum of €2.77 million alongside interest and arbitration costs.
As of October 14th this year—the approval date for the company’s latest financial statements—Narooma Limited noted it was still actively taking steps to recover the awarded amounts. While an HSE spokeswoman stated that the health service has “discharged any applicable payments (including interest) pursuant to such award,” the disparity between the company’s internal accounting notes and the HSE’s stance highlights a persistent friction point in the settlement execution.
High Court Litigation Against IDA Ireland
Beyond the HSE arbitration, Narooma Limited remains locked in a separate High Court battle with IDA Ireland. Filed in October 2020, this claim centers on allegations of tortious interference with the company’s commercial interests regarding the same ventilator procurement matter. The case was recently listed for mention in court and has been adjourned until November 27th, keeping the company’s legal exposure—and potential upside—in a state of flux.
John Ward, the director of Narooma Limited, confirmed the company intends to press ahead with the IDA Ireland claim. IDA Ireland has maintained that it is precluded from commenting due to the ongoing nature of the court proceedings. This litigation adds a layer of complexity to the firm’s balance sheet, which currently holds accumulated profits of close to €1.7 million and cash reserves of €1.8 million.
Market Sentiment and Institutional Exposure
Disclaimer: The information provided in this article is for educational and market analysis purposes only and does not constitute financial, investment, or legal advice. Always consult with a certified financial professional before making investment decisions.
